[{"from": "human", "value": "Please give me some details about this molecule. [C][C@H1][C][N][Branch2][Branch1][O][C][C][N][Ring1][=Branch1][C][=N][C][=Branch1][C][=O][N][Branch2][Ring1][N][C][=N][C][=Branch1][O][=C][Branch1][#Branch1][C][=C][Ring1][=Branch1][Ring1][O][F][C][=C][Branch1][Branch2][C][=C][C][=C][Ring1][=Branch1][F][O][C][=C][Branch1][N][C][=C][N][=C][Ring1][=Branch1][C][Branch1][C][C][C][C][C][=Branch1][C][=O][C][=C]"}, {"from": "gpt", "value": "The molecule is a pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations. It has a role as an antineoplastic agent. It is a member of acrylamides, a N-acylpiperazine, a pyridopyrimidine, a member of monofluorobenzenes, a member of methylpyridines, a tertiary carboxamide, a tertiary amino compound and a member of phenols."}]